News stories about Ligand Pharmaceuticals (NASDAQ:LGND) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.4892735515434 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Forget Teva (TEVA), Buy These 5 Drug Stocks Instead (finance.yahoo.com)
- CTI BioPharma Corp. (CTIC) vs. Ligand Pharmaceuticals (LGND) Head-To-Head Review (americanbankingnews.com)
- Ligand Pharmaceuticals Incorporated (LGND) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- LGND Crosses Above Average Analyst Target (nasdaq.com)
- Ligand Pharma (LGND) to Acquire Crystal Bioscience for $25 Million Plus Milestones (streetinsider.com)
LGND has been the subject of a number of analyst reports. TheStreet raised shares of Ligand Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $157.00 target price on shares of Ligand Pharmaceuticals in a research note on Thursday, October 5th. BidaskClub lowered shares of Ligand Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Roth Capital increased their target price on shares of Ligand Pharmaceuticals from $120.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Finally, Deutsche Bank AG increased their target price on shares of Ligand Pharmaceuticals from $103.00 to $104.00 and gave the stock a “hold” rating in a research note on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $133.25.
Ligand Pharmaceuticals (NASDAQ LGND) opened at 143.21 on Wednesday. Ligand Pharmaceuticals has a 52 week low of $87.50 and a 52 week high of $143.26. The firm’s 50-day moving average is $134.13 and its 200 day moving average is $120.07. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of 349.29 and a beta of 1.01.
Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.25 by $0.42. The company had revenue of $28.00 million during the quarter, compared to analysts’ expectations of $24.40 million. Ligand Pharmaceuticals had a return on equity of 5.05% and a net margin of 7.39%. The firm’s revenue was up 43.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.50 EPS. On average, equities research analysts expect that Ligand Pharmaceuticals will post $2.95 EPS for the current year.
In other news, insider Matthew W. Foehr sold 6,100 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $127.51, for a total transaction of $777,811.00. Following the completion of the sale, the insider now owns 101,020 shares in the company, valued at approximately $12,881,060.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John L. Higgins sold 5,483 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $125.00, for a total value of $685,375.00. Following the sale, the chief executive officer now owns 144,654 shares of the company’s stock, valued at approximately $18,081,750. The disclosure for this sale can be found here. Insiders sold a total of 37,208 shares of company stock valued at $4,733,796 in the last 90 days. 14.70% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/10/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-ligand-pharmaceuticals-lgnd-stock-price.html.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.